Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy

BACKGROUND: Concomitant tumor necrosis factor (TNF) neutralization in combination with immune checkpoint inhibitors (ICIs) reduces clinical immune-related adverse events (irAEs) and appears to improve antitumor efficacy in preclinical tumor models. Agonistic antibodies targeting costimulatory recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacoberger-Foissac, Celia, Blake, Stephen J, Liu, Jing, McDonald, Elizabeth, Triscott, Hannah, Nakamura, Kyohei, Smyth, Mark J, Teng, Michele WL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670957/
https://www.ncbi.nlm.nih.gov/pubmed/33199513
http://dx.doi.org/10.1136/jitc-2020-001687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670957/
https://www.ncbi.nlm.nih.gov/pubmed/33199513
http://dx.doi.org/10.1136/jitc-2020-001687

Ejemplares similares